What is Erasca?
Erasca operates as a clinical-stage precision oncology enterprise dedicated to the discovery, development, and commercialization of novel therapies targeting the RAS/MAPK signaling pathway. Recognizing that RAS mutations are among the most frequent drivers of oncogenesis, the company employs a holistic, multi-node inhibition strategy. By targeting multiple cooperative mechanisms in parallel, Erasca seeks to achieve a more comprehensive and synergistic shutdown of these promiscuous signaling pathways, potentially offering superior clinical outcomes for the millions of patients diagnosed annually with RAS/MAPK-driven cancers.
How much funding has Erasca raised?
Erasca has raised a total of $564M across 3 funding rounds:
Series A
$64M
Series B
$200M
Share Placement
$300M
Series A (2019): $64M, investors not publicly disclosed
Series B (2020): $200M led by LifeSci Venture Partner, ARCH Venture Partners, City Hill Ventures, Terra Magnum Capital Partners, Cormorant Asset Management , LLC, Colt Ventures, EDBI, and Invus
Share Placement (2021): $300M, investors not publicly disclosed
Key Investors in Erasca
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
City Hill Ventures
City Hill Ventures is a health care focused investment firm that specializes in founding, funding, and leading biotechnology and medical technology companies, providing both capital and active management expertise to its portfolio.
Colt Ventures
Colt Ventures is a diversified investment firm that focuses on biotechnology and other high-growth sectors, seeking significant value inflection points by backing proven management teams in both private and public markets.
What's next for Erasca?
With the support of its recent capital injection, Erasca is poised to transition its lead candidates through critical clinical milestones. The strategic focus remains on validating its multi-node therapeutic approach, which requires significant investment in both clinical trial infrastructure and molecular research. As the company scales, the emphasis will likely shift toward data readout cycles and potential regulatory engagement, ensuring that its pipeline of precision medicines can effectively address the unmet needs of patients with limited treatment options. The firm's ability to maintain its current pace of innovation will be central to its long-term objective of transforming the standard of care for RAS-driven diseases.
See full Erasca company page
